[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemoglobin-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemoglobin-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100608787","integrative-diagnosis-for-scd-and-other-rads-100608787",false,"NCT07206095","Integrative Diagnosis for SCD and Other RADs","Integrative Diagnosis of Sickle Cell Disease (SCD) and Other Rare Anemia Disorders (RADs) for Personalized Medicine","INTEGRA","Inclusion Criteria:\n\n* Patients sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia:\n* Sickle cell disease\n* Thalassemic syndromes\n* Congenital dyserythropoietic anemia\n* Enzymopathy\n* Unstable Hemoblogin \u002F Altered oxygen affinity\n* Hereditary stomatocytosis\n* Hereditary pyropoikilocytosis\n* Hereditary spherocytosis with severe anemia (\\\u003C8 g\u002FdL) or inconclusive diagnosis:\n* Patient with chronic hemolytic anemia and red cell smear compatible, but with:\n* EMA binding test: inconclusive or negative\n* Genetic testing: no definitive diagnosis (VUS or no findings)\n* Not transplanted or undergoing gene therapy at the time of inclusion. Patients with graft failure without a new transplant may be included.\n\nExclusion Criteria:\n\n* Carrier traits in autosomal recessive hereditary anemias","ALL",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","INTEGRA aims at enabling personalized medicine for RHADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.",[24,25,26,27,28,29,30,31,32],"Sickle Cell Disease","Thalassaemia","Congenital Dyserythropoietic Anemia (CDA)","Enzyme Disorder; Anemia","Spherocytosis, Hereditary","Stomatocytosis","Hemoglobin Disorder","Anemia Due to Membrane Defect","Rare Anemia Disorders",[34,35,36,37,38],"SICKLE CELL DISEASE","RARE ANEMIA DISORDERS","PERSONALIZED MEDICINE","DIAGNOSIS","EKTACYTOMETRY","RECRUITING","2025-09-25",{"date":42,"type":43},"2025-10-03","ACTUAL",{"date":45,"type":43},"2020-11-13",{"date":47,"type":20},"2028-05",{"name":49,"class":50},"Hospital Universitari Vall d'Hebron Research Institute","OTHER",9,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100565781","long-term-follow-up-study-for-individuals-with-hemoglobin-disorders-after-hematopoietic-cell-transplant-or-gene-therapy-100565781","NCT06646640","Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy","Inclusion Criteria:\n\n* Receipt, or planned receipt, of an allogeneic HSCT or infusion of genetically modified autologous cells for hemoglobin disorders within 15 years prior to enrollment\n\nExclusion Criteria:\n\n* Inability or unwillingness of research participant and\u002For legal guardian\u002F representative to provide written informed consent.",{"count":19,"type":20},"This is a prospective, longitudinal, non-therapeutic study which includes routine assessment for long-term effects, as per FDA guidelines after receipt of an allogeneic HCT or autologous genetically modified cellular products for hemoglobin disorders.\n\nPrimary objective:\n\n\\- To provide long term follow up, for individuals with hemoglobin disorders undergoing allogeneic hematopoietic stem cell transplantation (HCT) or receipt of an autologous genetically modified cellular product to treat their hemoglobinopathy. For individuals receiving a genetically modified cellular product, this long term follow up study is in accordance with the guidelines provided by the Food and Drug Administration (FDA).",[30],[62,63],"Transplant","Gene Therapy","2025-08-01",{"date":66,"type":43},"2025-08-07",{"date":68,"type":43},"2025-06-26",{"date":70,"type":20},"2050-01",{"name":72,"class":50},"St. Jude Children's Research Hospital",1]